Pharming preps filing for rare disease drug leniolisib after...

Pharming has taken a step closer to getting a second product to market, after its rare disease therapy leniolisib met its objectives in a pivotal trial, setting up regulatory filings in the

CSL accuses ex-exec, now at Pharming, of stealing trade secr...

Pharming buys rare disease drug from Novartis for $20m

Pharming has bought a late-stage pipeline drug aimed at a rare disease of the immune system from Novartis for $20 million up front, plus other payments further down the line.

Dutch biotech Pharming plans to challenge big pharma in rare...

The introduction of Shire’s preventive treatment for hereditary angioedema has shaken up the market for drugs for this rare disease.

FDA rejects Pharming's Ruconest HAE label expansion

The FDA has rejected Pharming’s application to expand the licence of Ruconest, for a use as prophylaxis for patients with the serious rare disease hereditary angioedema (HAE).